Rheumatic immune-related adverse events from cancer immunotherapy.

Volume: 14, Issue: 10, Pages: 569 - 579
Published: Oct 1, 2018
Abstract
Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and...
Paper Details
Title
Rheumatic immune-related adverse events from cancer immunotherapy.
Published Date
Oct 1, 2018
Volume
14
Issue
10
Pages
569 - 579
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.